spacer
home > ict > summer 2007 > value added trials
PUBLICATIONS
International Clinical Trials

Value Added Trials

The interest in the use of adaptive clinical trials is definitely rising – but why? Tom Parke of Tessella considers the expectations for these methods, and what they can offer

We are well versed in the pressures facing the pharmaceutical industry. Effective new compounds are becoming harder to find and harder to develop – the number of new drug registrations is falling and the time and cost of development is climbing. Society and regulators are becoming increasingly sensitive to potential safety issues, the diseases where there is still no effective treatment are usually the ones that are harder to study, and the compounds being found are often more difficult and costly to manufacture. Increasingly, regulators want sub-group analysis, which may help us identify the population where a compound is strongly effective, but in doing so drastically shrink the market for the compound.

ADAPTIVE CLINICAL TRIALS TO THE RESCUE?

One of the areas where pharmaceutical companies are trying to redress the balance is by running smarter and more sophisticated clinical trials. These require central randomisation to allocate a subject to a dose at the last possible moment. Initially, this was to allow the randomisation to be balanced, not just across the whole trial, but also within potentially significant sub-groups (old and young, male and female, and so on). Increasingly, the reason is to allow the randomisation to select which dose to give in order to optimise the way the trial learns about the dose response of the compound.

However, the more thirsty and sun-scorched a man is, the more likely he is to see a mirage. We shouldn’t seize on adaptive clinical trials simply from desperation because it is the current industry buzz phrase, or in the belief that they will magically transform the success rate of the drug development pipeline.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
4
     

There are no comments in regards to this article.

spacer
Tom Parke joined Tessella in 1996, and has worked on supporting adaptive clinical trials since 1998. He has overseen the development of algorithms, simulation tools and systems to support adaptive trials, as well as integrating adaptive algorithms with existing central randomisation and electronic data capture systems. Whilst currently working on his fifth dose-response adaptive trial, Tom is consulting with a number of international pharmaceutical companies, helping them to define the software systems they require to run adaptive clinical trials.
spacer
Tom Parke
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Mr Turhan Ozen Chief Cargo Officer at Turkish Airlines elected to the International Air Cargo Association (TIACA) Committee

Turhan Ozen, serving as Chief Cargo Officer at the global brand Turkish Airlines, was elected to the International Air Cargo Association (TIACA) Committee, the joint voice of the industry that aims to enhance the air cargo profile with intensive efforts towards the global standards.
More info >>

White Papers

Autoinjector testing made safe efficient and flexible

ZwickRoell

The autoinjector market is one of the fastest growing markets across almost all pharmaceutical applications. Studies expect a global market volume of approximately USD 2.5 billion by 2020, with pre-filled autoinjectors representing the largest market segment. There are a variety of tests that can be performed on autoinjectors, and these are well-demonstrated by the Zwick product portfolio. The Ulm-based company and specialist in testing systems offers a variety of testing systems that are already being successfully used by multiple pharmaceutical companies.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement